Half-Year 2022 Financial Performance

Biologics Financial and operational performance in H1 2022 1,625m Sales (CHF) 606m CORE EBITDA (CHF) +26.2%¹ +23.7% 37.3% CORE EBITDA Margin Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) - Lonza Growth supported by strong demand for commercial capacity Sustained customer demand for flexibility of IbexⓇ offering - New early phase capabilities in monoclonal antibodies launched to capture growing demand for new molecular formats -0.9ppts - Softer H1 margins compared to H1 2021 reflect product mix CORE definition: See appendix 19

View entire presentation